p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function

Zijun Y. Xu-Monette; Shanxiang Zhang; Xin Li; Ganiraju C. Manyam; Xiao-xiao Wang; Yi Xia; Carlo Visco; Alexandar Tzankov; Li Zhang; Santiago Montes-Moreno; Karen Dybkaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L. Richards; Eric D. Hsi; William W.L. Choi; J. Han van Krieken; Jooryung Huh; Maurilio Ponzoni; Andrés J.M. Ferreri; Xiaoying Zhao; Michael B. Møller; Ben M. Parsons; Jane N. Winter; Miguel A. Piris; L. Jeffrey Medeiros; Ken H. Young

doi:doi:10.18632/aging.100898

← Back

Research Paper Volume 8, Issue 2 pp 345—365

p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function

Figure 5. Prognostic analysis for p63 expression in DLBCL patients with wild- type and mutated TP53. (A-B) p63 expression correlated with significantly better survival outcomes in patients with high-risk (IPI > 2) DLBCL and WT-TP53. (C-D) p63 expression correlated with significantly better survival outcomes in patients with ABC-DLBCL and WT-TP53. (E) In patients with high-risk (IPI > 2) DLBCL and MUT-TP53, p63 expression did not correlate with survival outcomes although showed a trend toward better PFS. (F) p63 expression did not correlate with survival outcomes in patients with ABC-DLBCL and MUT-p53 overexpression. (G-H) p63 expression was associated with trends toward better survival outcomes in GCB-DLBCL patients with MUT-p53 overexpression (marginal P values).